Physician profile
Wayne E Kuhl
NPI 1215913884
$5,079.23
in general payments reported to CMS, 2019-2025
51 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $866 · 2021: $713 · 2022: $1,321 · 2023: $396 · 2024: $189 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.62 | 2019-2025 | |
| Amgen INC. | $747.70 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $437.64 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $406.55 | 2019-2025 | |
| Abbott Laboratories | $235.41 | 2020-2025 | Proclaim, Octrode, Freestyle Libre 3 |
| Allergan, INC. | $229.10 | 2019-2020 | |
| Cleerly, INC. | $212.26 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.95 | 2019-2020 | |
| Astellas Pharma US INC | $108.18 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $103.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.04 | 2019-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $90.85 | 2019 | |
| Eisai INC. | $75.78 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $65.01 | 2019-2023 | |
| Lilly USA, LLC | $64.54 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Kuhl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.